Advanced Gastroesophageal Junction Adenocarcinoma (DBCOND0120535)

Identifiers

Synonyms

Advanced gastro-esophageal junction adenocarcinoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Lexatumumab Nivolumab Paclitaxel Ramucirumab	treatment	2 / 3	recruiting
NCT06642857	Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.	No drug interventions	Not Available	Not Available	recruiting
NCT04391049	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery	Carboplatin Paclitaxel Suratadenoturev	treatment	1	active_not_recruiting
NCT04535401	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	Calcium Camptothecin Elimusertib Fluorouracil Irinotecan Leucovorin Levoleucovorin	treatment	1	active_not_recruiting
NCT04704661	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Ceralasertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT05041153	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Lenvatinib Pembrolizumab	treatment	0	recruiting
NCT05649163	Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy	Disitamab vedotin	Not Available	Not Available	not_yet_recruiting
NCT04890392	Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC	Oxaliplatin Tislelizumab	treatment	2	unknown_status
NCT05677490	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Fluorouracil Irinotecan Leucovorin Nivolumab Oxaliplatin	treatment	3	recruiting
NCT03395847	Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma	Pembrolizumab	treatment	0	completed
NCT06028737	Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer	Docetaxel Fluorouracil Leucovorin Oxaliplatin	treatment	2 / 3	recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting